Arterial hypertension (BASKET)

LE WE PMID CA

Arterial hypertension (BASKET)

225

Arterielle Hypertonie (allg)

20 HETE

Aldosterone (Hyperaldosteronism Aldosteronism)

Aliskiren

Aminopeptidase A

Amlodipine

Arterial hypertension (BASKET)

Autonomous nervous system (BASKET)

Baroreceptor (BASKET)

Baroreceptor (stimulation)

Baroreflex

Blood vessels (Physiology)

Blood vessels (Resistance artery)

Calcium (Physiology renal)

Cardiorenal syndrome

Cardiovascular risk

Chlorthalidone

CNS (Circumventricular organs)

CNS (Intracerebral bleeding)

CNS (Stroke BASKET)

Diabetes mellitus (Involvement heart and vessels)

Diabetes mellitus T2DM (Type2)

Dinucleoside polyphosphates

Diuretic agents (Thiazides)

Drug interaction check

Endogenous ouabain

Endothelial dysfunction

Epoxide hydrolase

Epoxyeicosatrienoic acid EET

ERSNA efferent renal sympathetic nervous activity

Eye (Diseases)

Eye (Retinopathy hypertensive)

G protein coupled receptor kinase4

GRK4

Heart (Echocardiography)

Heart (Electrocardiography)

Heme oxygenase

Hemodialysis (BASKET)

Hydrochlorothiazide

Indapamide

Ion channel (Sodium ENaC)

Ion channel (Sodium)

Ion channel (TRP Family)

Kidney (Anatomy)

Kidney (Chronic renal failure)

Kidney (Failure acute)

Kidney (Microcirculation)

Kidney (Tubulus)

Leptin

Liddle s syndrome

Lysophosphatidate

Mechanotransduction

Melatonin

Metabolic syndrome

NADPH oxidase

NCC

NCX1

Nephroangiosclerosis malignant

Nephrolithiasis

Nephropathy (hypertensive)

Nephroprotective renoprotective agents

NKCC1

NKCC2

Nucleus tractus solitarius

Oat3

Obesity (BASKET)

Oligomeganephronia

Olmesartan

Organum vasculosum laminae terminalis

Orthostatic hypertension

Osmosensor

OSR1

Puls wave analysis

RAAS (Local Kidney)

RAAS (Renin angiotensin system)

Receptor (PPAR)

Renal denervation therapeutic

RGS protein family

Sclerodermia

Sleep apnea (obstructive)

Sodium (Salt)

SPAK

Statin

Subfornical organ

Sympathetic nervous system

Systemic lupus erythematosus

Thioredoxin

Thrombophilia

Transporter (Organic molecules)

Transporter (Sodium and calcium)

Transporter (Sodium and chloride)

Transporter (Sodium potassium and chloride)

TRPM7

TRPV1

Vanilloids

WNK

WNK1

WNK2

WNK3

WNK4

1978 1	Nonpharmacologic control of essential hypertension in man: a critical review of the experimental literature. [356079] Psychosom Med 40(4): 294-320 (1978)
1978 2	Relaxation methods and the control of blood pressure. [356077] Psychosom Med 40(4): 273-5 (1978)
2001 3	ABC of hypertension: The pathophysiology of hypertension. [11302910] BMJ 322(7291): 912-6 (2001)
1965 4	Hyperpiesis: high blood-pressure without evident cause: essential hypertension. [5318057] Br Med J 2(5469): 1021-6 concl (1965)
1965 5	Hyperpiesis; high blood-pressure without evident cause: essential hypertension. [5318678] Br Med J 2(5468): 959-68 contd (1965)
2010 6	Angiotensin receptor blockers for management of hypertension. [20531060] South Med J 103(7): 669-73 (2010)
2010 7	Angiotensin-receptor blockers for the management of hypertension: new insights, new challenges. [20531050] South Med J 103(7): 599-600 (2010)
2009 8	Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. [19834426] South Med J 102(10 Suppl): S1-S12 (2009)
2008 9	Resistant hypertension: identifying causes and optimizing treatment regimens. [18364619] South Med J 101(2): 166-73 (2008)
2007 10	Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics. [17458399] South Med J 100(4): 386-92 (2007)
2001 11	Antihypertensive medications. [11780676] South Med J 94(11): 1071-3 (2001)
2001 12	Hypertension. Medication update. [11780675] South Med J 94(11): 1065-70 (2001)
2000 13	Pitfalls in the diagnosis and management of systolic hypertension. [10728509] South Med J 93(3): 256-9 (2000)
2000 14	Controlling hypertension in the elderly. [10787447] QJM 93(4): 203-5 (2000)
1999 15	Management of hypertension in patients developing end-stage renal failure. [10627872] QJM 92(9): 519-25 (1999)
2003 16	Hypertension: a review of therapeutic options. [12971591] Manag Care 12(8 Suppl Hypertension): 34-44 (2003)
1999 17	Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. [10218745] Arch Intern Med 159(7): 670-4 (1999)
2004 18	Baroreflex failure: a neglected type of secondary hypertension. [15366697] Neth J Med 62(5): 151-5 (2004)
2003 19	New developments in the treatment of hypertension: are some antihypertensives more equal than others? [12918545] Neth J Med 61(5 Suppl): 13-8 (2003)
2009 20	Beta-blockers for hypertension: are they going out of style? [19726558] Cleve Clin J Med 76(9): 533-42 (2009)
2008 21	What is the proper workup of a patient with hypertension? [18788227] Cleve Clin J Med 75(9): 663-72 (2008)
2007 22	A different approach to resistant hypertension. [17569203] Cleve Clin J Med 74(6): 449-56 (2007)
1979 23	Pathogenesis of hypertensive retinopathy: a review. [399635] J R Soc Med 72(5): 362-5 (1979)
2007 24	Rebuttal: Do beta-blockers have a role in treating hypertension? Yes. [17872734] Can Fam Physician 53(5): 800-3 (2007)
2007 25	Do beta-blockers have a role in treating hypertension? No. [17872703] Can Fam Physician 53(4): 614-21 (2007)
2007 26	Do beta-blockers have a role in treating hypertension? Yes. [17872702] Can Fam Physician 53(4): 614-21 (2007)
1998 27	Echocardiography for primary care evaluation of hypertension. [9870123] Can Fam Physician 44(-): 2702-6 (1998)
2003 28	Clinical review: the management of hypertensive crises. [12974970] Crit Care 7(5): 374-84 (2003)
2003 29	Hypertension in the critically ill patient. [16573454] Crit Care Resusc 5(1): 24-42 (2003)
2000 30	Diagnosis and treatment of hypertension in children and adolescents. [10863171] Can J Cardiol 16(6): 801-11 (2000)
1996 31	Resistant hypertension: an overview. [8842136] Can J Cardiol 12(9): 822-8 (1996)
2003 32	Calcium antagonists in patients with type 2 diabetes and hypertension. [12847562] Cardiovasc Drug Rev 21(2): 105-18 (2003)
2010 33	Is it time to target prehypertension. [21050419] Cardiovasc Ther 28(6): 337-8 (2010)
2011 34	5-hydroxtryptamine receptors in systemic hypertension: an arterial focus. [20433685] Cardiovasc Ther 29(1): 54-67 (2011)
2009 35	Hypertension in the very elderly: Brief review of management. [19653187] Cardiol J 16(4): 379-85 (2009)
2008 36	Hypertension and microvascular remodelling. [18250145] Cardiovasc Res 78(2): 274-85 (2008)
2006 37	Redox signaling in hypertension. [16765337] Cardiovasc Res 71(2): 247-58 (2006)
2004 38	Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. [14736540] Cardiovasc Res 61(2): 238-46 (2004)
2002 39	Sex hormones and hypertension. [11861040] Cardiovasc Res 53(3): 688-708 (2002)
2000 40	The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy. [10728317] Cardiovasc Res 45(1): 82-91 (2000)
1987 41	The large studies in hypertension: what have they shown? [3326632] Br J Clin Pharmacol 24 Suppl 1(-): 3S-14S (1987)
1986 42	The management of hypertension. [3530297] Br J Clin Pharmacol 21 Suppl 2(-): 129S-142S (1986)
1986 43	Salt and hypertension. [3530296] Br J Clin Pharmacol 21 Suppl 2(-): 123S-128S (1986)
1980 44	Pharmacology of centrally acting hypotensive drugs. [6104975] Br J Clin Pharmacol 10 Suppl 1(-): 13S-20S (1980)
2005 45	The vanilloid receptor and hypertension. [15715923] Acta Pharmacol Sin 26(3): 286-94 (2005)
2007 46	Case study: pearls in hypertension pharmacotherapy. [17605506] J Manag Care Pharm 13(5 Suppl): S13-6 (2007)
2007 47	Overview of physiology, vascular biology, and mechanisms of hypertension. [17605504] J Manag Care Pharm 13(5 Suppl): S6-8 (2007)
2010 48	Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact. [20694060] Core Evid 4(): 1-11 (2010)
2000 49	Clinical overview of antihypertensive classes--clinically relevant differences: myths or facts? Based on a presentation by Alan H. Gradman, MD. [10977460] Am J Manag Care 6(4 Suppl): S197-210 (2000)
1979 50	The hypertensive patient: 1. Is treatment beneficial? [455174] Can Med Assoc J 120(11): 1319-20 (1979)
1979 51	Membranes and bile formation. Composition of several mammalian biles and their membrane-damaging properties. [35277] Biochem J 178(1): 201-8 (1979)
1975 52	Aldosterone and renin in essential hypertension. [1098756] Can Med Assoc J 113(5): 421-31 (1975)
1965 53	NEWER DRUGS IN THE TREATMENT OF HYPERTENSION. [14289140] Can Med Assoc J 92(-): 918-22 (1965)
2007 54	Hypertensive crises: challenges and management. [17565029] Chest 131(6): 1949-62 (2007)
2000 55	The diagnosis and management of hypertensive crises. [10893382] Chest 118(1): 214-27 (2000)
1988 56	Calcium antagonists in the treatment of hypertension. An overview. [3286142] Chest 93(6): 1251-3 (1988)
2008 57	Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. [18574054] Circulation 117(25): e510-26 (2008)
2008 58	Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. [18490538] Circulation 117(20): 2706-15; discussion 2715 (2008)
2008 59	Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. [18490537] Circulation 117(20): 2691-704; discussion 2705 (2008)
2007 60	Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. [17502569] Circulation 115(21): 2761-88 (2007)
2006 61	Preventing vascular events due to elevated blood pressure. [16684871] Circulation 113(18): 2166-8 (2006)
2005 62	Natural history of hypertension subtypes. [15753224] Circulation 111(9): 1094-6 (2005)
2004 63	Hypertensive therapy: Part II. [15226224] Circulation 109(25): 3081-8 (2004)
2004 64	Hypertensive therapy: Part I. [15210612] Circulation 109(24): 2953-8 (2004)
2002 65	Evaluation and treatment of patients with systemic hypertension. [12034648] Circulation 105(21): 2458-61 (2002)
2000 66	New issues in the treatment of isolated systolic hypertension. [10973833] Circulation 102(10): 1079-81 (2000)
2000 67	Essential hypertension : part II: treatment. [10653838] Circulation 101(4): 446-53 (2000)
2000 68	Essential hypertension. Part I: definition and etiology. [10645931] Circulation 101(3): 329-35 (2000)
2005 69	Management of hypertension in elderly diabetic patients. [16415770] Diabetes Metab 31 Spec No 2(): 5S82-5S91 (2005)
2008 70	Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. [18852183] Eur Heart J 29(21): 2669-80 (2008)
2007 71	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). [17562668] Eur Heart J 28(12): 1462-536 (2007)
2000 72	Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? [11032692] Eur Heart J 21(20): 1653-65 (2000)
1999 73	Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension. [10075137] Eur Heart J 20(1): 11-24 (1999)
2003 74	Cardiac and vascular pathophysiology in hypertension. [12923045] Heart 89(9): 1104-9 (2003)
2001 75	Essential hypertension: the heart and hypertension. [11559694] Heart 86(4): 467-75 (2001)
2008 76	Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. [18391085] Hypertension 51(6): 1403-19 (2008)
2006 77	Mechanisms of sympathetic activation in obesity-related hypertension. [17000932] Hypertension 48(5): 787-96 (2006)
2006 78	Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care? [16735646] Hypertension 48(1): 1-7 (2006)
2005 79	Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. [16009786] Hypertension 46(2): 386-92 (2005)
2005 80	Management of prehypertension. [15897368] Hypertension 45(6): 1056-61 (2005)
2005 81	Obesity-associated hypertension: new insights into mechanisms. [15583075] Hypertension 45(1): 9-14 (2005)
1993 82	1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. [8349333] Hypertension 22(3): 392-403 (1993)
2006 83	Thiazide diuretics in the treatment of hypertension: an update. [16565243] J Am Soc Nephrol 17(4 Suppl 2): S25-9 (2006)
1998 84	Malignant hypertension and hypertensive emergencies. [9440098] J Am Soc Nephrol 9(1): 133-42 (1998)
2008 85	Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: a review of controlled trials. [18587726] J Nephrol 21(3): 374-83 (2008)
2006 86	Central arterial pressure and arterial pressure pulse: new views entering the second century after Korotkov. [16901029] Mayo Clin Proc 81(8): 1057-68 (2006)
2006 87	The role of combination therapy in the management of hypertension. [16714336] Nephrol Dial Transplant 21(6): 1469-73 (2006)
1997 88	Malignant hypertension: still a challenge. [9306367] Nephrol Dial Transplant 12(9): 2019-23 (1997)
2004 89	The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. [15286277] Pediatrics 114(2 Suppl 4th Report): 555-76 (2004)
2003 90	Classification and definition of disorders causing hypertonia in childhood. [12509602] Pediatrics 111(1): e89-97 (2003)
2004 91	Use of diuretics in cardiovascular disease: (2) hypertension. [15138316] Postgrad Med J 80(943): 271-6 (2004)
1993 92	A risk-benefit analysis for the treatment of hypertension. [8290406] Postgrad Med J 69(816): 764-74 (1993)
1993 93	Noninvasive 24 hour ambulatory blood pressure monitoring: current status. [8321789] Postgrad Med J 69(810): 255-67 (1993)
1993 94	Paediatrics--Part I. [8497430] Postgrad Med J 69(809): 171-85 (1993)
1991 95	Hypertension. [2062770] Postgrad Med J 67(785): 230-46 (1991)
2005 96	Blood pressure reduction for vascular risk: is there a price to be paid? [15860749] Stroke 36(6): 1308-13 (2005)
2004 97	Blood pressure and stroke: an overview of published reviews. [14976329] Stroke 35(3): 776-85 (2004)
2003 98	Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is the key. [12702834] Stroke 34(5): 1333-4 (2003)
2003 99	Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is not the key. [12702833] Stroke 34(5): 1334-5 (2003)
1991 100	Management of mild hypertension. Selecting an antihypertensive regimen. [2024512] West J Med 154(1): 78-87 (1991)
1984 101	Malignant or accelerated hypertension. [6372248] West J Med 140(4): 575-82 (1984)
1980 102	Antihypertensive pharmacology. [6992462] West J Med 132(5): 430-9 (1980)
1979 103	Nontraditional problems of antihypertensive management. [18748465] West J Med 131(3): 179-92 (1979)
2008 104	Resistant hypertension: an overview of evaluation and treatment. [19022154] J Am Coll Cardiol 52(22): 1749-57 (2008)
2007 105	Hypertension in the young: preventing the evolution of disease versus prevention of clinical events. [17719469] J Am Coll Cardiol 50(9): 840-2 (2007)
2005 106	Home blood pressure measurement: a systematic review. [16139119] J Am Coll Cardiol 46(5): 743-51 (2005)
2005 107	Recent hypertension trials: implications and controversies. [15766813] J Am Coll Cardiol 45(6): 813-27 (2005)
2001 108	Pulse pressure--a review of mechanisms and clinical relevance. [11263624] J Am Coll Cardiol 37(4): 975-84 (2001)
1996 109	Primary renal abnormalities in hereditary hypertension. [8872945] Kidney Int 50(3): 717-31 (1996)
2001 110	Molecular mechanisms of human hypertension. [11239411] Cell 104(4): 545-56 (2001)
2006 111	Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. [16754904] CMAJ 174(12): 1737-42 (2006)
2000 112	Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers. [10934984] CMAJ 163(2): 188-92 (2000)
2000 113	Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 1: Thiazide diuretics. [10920733] CMAJ 163(1): 57-60 (2000)
1999 114	Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? [10420860] CMAJ 161(1): 25-32 (1999)
1993 115	Integration of factors controlling vascular tone. Overview. [8267212] Anesthesiology 79(6): 1368-80 (1993)
1977 116	Psychological methods in treatment of hypertension: a review. [328023] Br Heart J 39(6): 587-93 (1977)
1971 117	What is hypertension? Recent studies on neurogenic hypertension. [4929434] Br Heart J 33(-): Suppl:109-12 (1971)
2003 118	Better blood pressure control: how to combine drugs. [12574784] J Hum Hypertens 17(2): 81-6 (2003)
2000 119	Hypertension and the prothrombotic state. [11095159] J Hum Hypertens 14(10-11): 687-90 (2000)
2000 120	Cerebral complications of hypertension. [11095154] J Hum Hypertens 14(10-11): 605-16 (2000)
1999 121	Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital. [10333343] J Hum Hypertens 13(4): 249-55 (1999)
1998 122	Isolated systolic hypertension: pathophysiology, consequences and therapeutic benefits. [9783491] J Hum Hypertens 12(9): 621-6 (1998)
1998 123	Secondary hypertension in the elderly. [9783488] J Hum Hypertens 12(9): 603-6 (1998)
2007 124	Recent update in the management of hypertension. [18380058] Acta Med Indones 39(4): 186-91 (2007)
2010 125	Pivotal role of the kidney in hypertension. [20610969] Am J Med Sci 340(1): 30-2 (2010)
2007 126	NKCC1 as a regulator of vascular tone and a novel target for antihypertensive therapeutics. [17308011] Am J Physiol Heart Circ Physiol 292(5): H2035-6 (2007)
2008 127	The beginning of a fantastic, unanswered question: is 5-HT involved in systemic hypertension? [18775854] Am J Physiol Heart Circ Physiol 295(3): H915-H916 (2008)
2009 128	A new piece in the hypertension puzzle: central blood pressure regulation by sex steroids. [19801489] Am J Physiol Heart Circ Physiol 297(5): H1583-4 (2009)
2009 129	Angiotensin II, mechanotransduction, and pulsatile arterial hemodynamics in hypertension. [19734358] Am J Physiol Heart Circ Physiol 297(5): H1567-75 (2009)
2010 130	Endogenous cardiotonic steroids and salt-sensitive hypertension. [20347967] Biochim Biophys Acta 1802(12): 1230-6 (2010)
2010 131	Genetics of hypertension: from experimental animals to humans. [20035862] Biochim Biophys Acta 1802(12): 1299-308 (2010)
2007 132	TRP channels in hypertension. [17399958] Biochim Biophys Acta 1772(8): 895-906 (2007)
2010 133	The effects of biofeedback in diabetes and essential hypertension. [20622080] Cleve Clin J Med 77 Suppl 3(-): S68-71 (2010)
2011 134	Goal-directed antihypertensive therapy: lower may not always be better. [21285345] Cleve Clin J Med 78(2): 123-33 (2011)
2009 135	Beyond office sphygmomanometry: ways to better assess blood pressure. [19884295] Cleve Clin J Med 76(11): 657-62 (2009)
2010 136	Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. [20921433] Hypertension 56(5): 780-800 (2010)
2010 137	Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. [20937968] Hypertension 56(5): 765-73 (2010)
2010 138	Salt and aldosterone: a concert of bad effects. [20921423] Hypertension 56(5): 804-5 (2010)
2010 139	DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. [20921424] Hypertension 56(5): 806-7 (2010)
2010 140	Sympathetic nervous activation in essential hypertension: commonly neglected as a therapeutic target, usually ignored as a drug side effect. [20368501] Hypertension 55(5): 1090-1 (2010)
2010 141	Drug combinations in the treatment of hypertension: never-ending novelty. [20479332] Hypertension 56(1): 22-3 (2010)
2010 142	Strategies and goals for hypertension control in patients with diabetes mellitus. [20497989] Hypertension 56(1): 24-5 (2010)
2010 143	Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications. [20497993] Hypertension 56(1): 10-6 (2010)
2010 144	Electrical carotid baroreceptor stimulation in resistant hypertension. [20100993] Hypertension 55(3): 607-9 (2010)
2010 145	Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. [20176994] Hypertension 55(4): 813-8 (2010)
2010 146	Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients. [20212274] Hypertension 55(4): 819-31 (2010)
2010 147	Unresolved issues in the management of hypertension. [20215564] Hypertension 55(4): 832-4 (2010)
2008 148	Transient receptor potential vanilloid type 1 receptors in hypertensive renal damage: a promising therapeutic target? [18606896] Hypertension 52(2): 213-4 (2008)
2004 149	Novel mechanisms responsible for postmenopausal hypertension. [15023933] Hypertension 43(5): 918-23 (2004)
2004 150	Hypertension and cyclooxygenase-2 inhibitors: target: the renal medulla. [15314033] Hypertension 44(4): 396-7 (2004)
2004 151	Alcohol-associated hypertension: when one drinks makes a difference. [15492132] Hypertension 44(6): 805-6 (2004)
2009 152	The pump, the exchanger, and endogenous ouabain: signaling mechanisms that link salt retention to hypertension. [19104005] Hypertension 53(2): 291-8 (2009)
2009 153	Mitochondrial dysfunction and mitochondrial-produced reactive oxygen species: new targets for neurogenic hypertension? [19114641] Hypertension 53(2): 112-4 (2009)
2009 154	Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. [19273737] Hypertension 53(5): 860-6 (2009)
2007 155	Treating resistant hypertension with a neglected old drug. [17309945] Hypertension 49(4): 763-4 (2007)
2007 156	Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. [17309949] Hypertension 49(4): 792-8 (2007)
2005 157	Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. [15809363] Hypertension 45(5): 880-6 (2005)
2005 158	Baroreflex failure. [15837841] Hypertension 45(5): 834-9 (2005)
2009 159	Postmenopausal hypertension: mechanisms and therapy. [19470884] Hypertension 54(1): 11-8 (2009)
2009 160	Mitochondrial Thioredoxin: novel regulator for NADPH oxidase and angiotensin II-induced hypertension. [19506095] Hypertension 54(2): 224-5 (2009)
2009 161	Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. [19720958] Hypertension 54(4): 690-7 (2009)
2005 162	The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies. [16103270] Hypertension 46(3): 463-8 (2005)
2005 163	Neurogenic mechanisms and salt sensitivity. [16230507] Hypertension 46(6): 1259-60 (2005)
2005 164	Baroreflexes in hypertension: a mystery revisited. [16216986] Hypertension 46(5): 1095-6 (2005)
2008 165	A tale of two patients with Mendelian hypertension. [18268135] Hypertension 51(3): 609-14 (2008)
2008 166	Pathogenesis of elevated peripheral pulse pressure: some reflections and thinking forward. [18071060] Hypertension 51(1): 33-6 (2008)
2008 167	Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? [18086947] Hypertension 51(2): 168-71 (2008)
2008 168	Update on the use of antihypertensive drugs in pregnancy. [18259046] Hypertension 51(4): 960-9 (2008)
2008 169	Aminopeptidase A: could it be a novel target for neurogenic hypertension? [18362227] Hypertension 51(5): 1273-4 (2008)
2008 170	G protein-coupled receptor kinase 4: role in blood pressure regulation. [18347232] Hypertension 51(6): 1449-55 (2008)
2008 171	Kidney in hypertension: guyton redux. [18332286] Hypertension 51(4): 811-6 (2008)
2008 172	Pediatric antihypertensive trial failures: analysis of end points and dose range. [18332283] Hypertension 51(4): 834-40 (2008)
2008 173	Kidney and circadian blood pressure rhythm. [18316650] Hypertension 51(4): 827-8 (2008)
2005 174	Vascular development, pulse pressure, and the mechanisms of hypertension. [15911744] Hypertension 46(1): 205-9 (2005)
2009 175	Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. [19822798] Hypertension 54(6): 1195-201 (2009)
2009 176	Another major role for dietary sodium reduction: improving blood pressure control in patients with resistant hypertension. [19620515] Hypertension 54(3): 444-6 (2009)
2010 177	RGS2 proteins regulate blood pressure. [20947628] J Am Soc Nephrol 21(11): 1809-10 (2010)
2004 178	Overview: mechanisms of hypertension: cells, hormones, and the kidney. [15284282] J Am Soc Nephrol 15(8): 1971-3 (2004)
2003 179	Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. [12819310] J Am Soc Nephrol 14(7 Suppl 2): S92-8 (2003)
2005 180	Prenatal programming of hypertension: lessons from experimental models. [16049066] J Am Soc Nephrol 16(9): 2545-56 (2005)
2007 181	Salt-sensitive hypertension--update on novel findings. [17210585] Nephrol Dial Transplant 22(4): 992-5 (2007)
2010 182	Hypertension in children and adolescents: epidemiology and natural history. [19421783] Pediatr Nephrol 25(7): 1219-24 (2010)
2009 183	At the bottom of the differential diagnosis list: unusual causes of pediatric hypertension. [18320238] Pediatr Nephrol 24(11): 2137-46 (2009)
2009 184	Treatment of hypertension in children and adolescents. [17690916] Pediatr Nephrol 24(10): 1939-49 (2009)
2009 185	Heritable forms of hypertension. [17647025] Pediatr Nephrol 24(10): 1929-37 (2009)
2010 186	Neural set point for the control of arterial pressure: role of the nucleus tractus solitarius. [20064256] Biomed Eng Online 9(-): 4 (2010)
2010 187	The search for strategies to control hypertension. [20823382] Circulation 122(12): 1141-3 (2010)
2003 188	Morning surge in blood pressure. [12642350] Circulation 107(10): 1347 (2003)
2005 189	Diuretics for hypertension. [16145005] Circulation 112(10): e127-9 (2005)
2011 190	Mevalonate pathway is a novel target for hypertension. [21532185] Circ J 75(6): 1318-9 (2011)
2011 191	Transient receptor potential melastatin 7 (TRPM7) cation channels, magnesium and the vascular system in hypertension. [21150127] Circ J 75(2): 237-45 (2011)
2010 192	Sympathoinhibitory effects of atorvastatin in hypertension. [21088328] Circ J 74(12): 2552-3 (2010)
2009 193	Orthostatic hypertension: a measure of blood pressure variation for predicting cardiovascular risk. [19430163] Circ J 73(6): 1002-7 (2009)
2003 194	Intrauterine undernutrition--renal and vascular origin of hypertension. [14613851] Cardiovasc Res 60(2): 228-34 (2003)
2008 195	The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway. [18843116] J Cell Sci 121(Pt 20): 3293-304 (2008)
2010 196	Epithelial Na+ channel (ENaC), hormones, and hypertension. [20460373] J Biol Chem 285(31): 23527-31 (2010)
2010 197	Role of epithelial sodium channels and their regulators in hypertension. [20624922] J Biol Chem 285(40): 30363-9 (2010)
2009 198	Management of blood pressure for acute and recurrent stroke. [19390077] Stroke 40(6): 2251-6 (2009)
2010 199	Blood pressure in young adults. [21265492] Rev Port Cardiol 29(10): 1495-508 (2010)
2010 200	High blood pressure in the pediatric age group. [20635566] Rev Port Cardiol 29(3): 413-32 (2010)
2005 201	Hypertension in children and adolescents. [16335283] Rev Port Cardiol 24(9): 1091-4 (2005)
2008 202	Some reflections on prehypertension. [19280998] Rev Port Cardiol 27(12): 1583-9 (2008)
2008 203	Malignant hypertension, severe hypertensive retinopathy and malignant nephroangiosclerosis. [18551923] Rev Port Cardiol 27(3): 373-9 (2008)
2009 204	Update in primary aldosteronism. [19737921] J Clin Endocrinol Metab 94(10): 3623-30 (2009)
2010 205	Hyperosmotic activation of CNS sympathetic drive: implications for cardiovascular disease. [20603334] J Physiol 588(Pt 18): 3375-84 (2010)
2006 206	Topics on the Na+/Ca2+ exchanger: role of vascular NCX1 in salt-dependent hypertension. [16960423] J Pharmacol Sci 102(1): 32-6 (2006)
2009 207	Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. [19563527] Br J Pharmacol 157(7): 1142-53 (2009)
2009 208	Endothelium-dependent contractions and endothelial dysfunction in human hypertension. [19630832] Br J Pharmacol 157(4): 527-36 (2009)
2004 209	Salt handling and hypertension. [15085183] J Clin Invest 113(8): 1075-81 (2004)
2005 210	Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. [15788708] Physiol Rev 85(2): 679-715 (2005)
2009 211	Physiological significance of heme oxygenase in hypertension. [19027871] Int J Biochem Cell Biol 41(5): 1025-33 (2009)
2011 212	Treatment strategies for resistant arterial hypertension. [22114648] Dtsch Arztebl Int 108(43): 725-31 (2011)
2005 213	Abnormalities of the resistance vasculature in hypertension: correction by vasodilator therapy. [16415495] Pharmacol Rep 57 Suppl(-): 144-50 (2005)
2008 214	Angiotensin II type 1 receptor blocker combined with hydrochlorothiazide for the treatment of hypertension. [18591834] Intern Med 47(13): 1163-4 (2008)
2004 215	Systolic hypertension in older persons. [15339901] JAMA 292(9): 1074-80 (2004)
2004 216	The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. [14968142] Can J Cardiol 20(1): 41-54 (2004)
2004 217	The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension. [14968143] Can J Cardiol 20(1): 55-9 (2004)
2004 218	The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. [14968141] Can J Cardiol 20(1): 31-40 (2004)
2003 219	Potential role of lysophosphatidic acid in hypertension and atherosclerosis. [14760444] Can J Cardiol 19(13): 1525-36 (2003)
2007 220	Night-time blood pressure patterns and target organ damage: a review. [17311119] Can J Cardiol 23(2): 132-8 (2007)
2007 221	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. [17534459] Can J Cardiol 23(7): 529-38 (2007)
2007 222	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. [17534460] Can J Cardiol 23(7): 539-50 (2007)
2007 223	More medications, fewer pills: combination medications for the treatment of hypertension. [17534465] Can J Cardiol 23(7): 573-6 (2007)
2007 224	Treatment of hypertension in patients with nondiabetic chronic kidney disease. [17534470] Can J Cardiol 23(7): 595-601 (2007)
2007 225	Musings regarding hypertension. [17593584] Can J Cardiol 23(7): 603-4 (2007)
2009 226	Resistant hypertension. [19417863] Can J Cardiol 25(5): 315-7 (2009)
2009 227	2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update. [19417857] Can J Cardiol 25(5): 271-7 (2009)
2009 228	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. [19417858] Can J Cardiol 25(5): 279-86 (2009)
2009 229	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. [19417859] Can J Cardiol 25(5): 287-98 (2009)
2009 230	Hypertension in diabetes: a call to action. [19417860] Can J Cardiol 25(5): 299-302 (2009)
2009 231	Hypertension in dialysis and kidney transplant patients. [19417862] Can J Cardiol 25(5): 309-14 (2009)
2008 232	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. [18548143] Can J Cardiol 24(6): 465-75 (2008)
2008 233	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. [18548142] Can J Cardiol 24(6): 455-63 (2008)
2010 234	Diagnostic modalities of the most common forms of secondary hypertension. [21169184] Hellenic J Cardiol 51(6): 518-29 (2010)
2008 235	Beta-blockers in the treatment of hypertension: latest data and opinions. [18350781] Hellenic J Cardiol 49(1): 37-47 (2008)
2010 236	Strategies for initial management of hypertension. [21150005] Indian J Med Res 132(5): 531-42 (2010)
2010 237	Aliskiren and valsartan combination therapy for the management of hypertension. [20859542] Vasc Health Risk Manag 6(-): 711-22 (2010)
2011 238	Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. [21966222] Vasc Health Risk Manag 7(-): 577-84 (2011)
2011 239	Treatment options for hypertension in high-risk patients. [21468174] Vasc Health Risk Manag 7(-): 137-41 (2011)
2011 240	Olmesartan/amlodipine: a review of its use in the management of hypertension. [21490944] Vasc Health Risk Manag 7(-): 183-92 (2011)
2007 241	Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. [18200799] Vasc Health Risk Manag 3(6): 783-95 (2007)
2010 242	The 'neuroadrenergic hypothesis' in hypertension: current evidence. [20008032] Exp Physiol 95(5): 581-6 (2010)
2005 243	Sympatho-renal interactions in the determination of arterial pressure: role in hypertension. [15604108] Exp Physiol 90(2): 183-7 (2005)
2005 244	Role of leptin in obesity-related hypertension. [16105937] Exp Physiol 90(5): 683-8 (2005)
2008 245	A sympathetic view of the sympathetic nervous system and human blood pressure regulation. [18326553] Exp Physiol 93(6): 715-24 (2008)
2010 246	Redox unbalance: NADPH oxidase as therapeutic target in blood pressure control. [20549031] Arq Bras Cardiol 94(5): 643-51, 684-93 (2010)
2007 247	Occurrence rate and clinical predictors of hypertensive pseudocrisis in emergency room care. [17589634] Arq Bras Cardiol 88(5): 579-84 (2007)
2007 248	Mechanisms and treatment of resistant hypertension. [17664996] Arq Bras Cardiol 88(6): 683-92 (2007)
2011 249	Dutch guideline for the management of hypertensive crisis -- 2010 revision. [21646675] Neth J Med 69(5): 248-55 (2011)
2010 250	Hypertension in pediatric patients. [20622277] Indian Pediatr 47(6): 473-4 (2010)
2006 251	Childhood hypertension. [16651671] Indian Pediatr 43(4): 326-33 (2006)
2007 252	Evaluation and management of hypertension. [17351301] Indian Pediatr 44(2): 103-21 (2007)
2004 253	Genetics of essential hypertension. [14764624] Hum Mol Genet 13 Spec No 1(-): R169-75 (2004)
2007 254	Genetic basis of polygenic hypertension. [17911162] Hum Mol Genet 16 Spec No. 2(-): R195-202 (2007)
2011 255	Hypertension in people with type 2 diabetes: Update on pharmacologic management. [21918140] Can Fam Physician 57(9): 997-1002, e347-53 (2011)
2010 256	Role of the kidney in the prenatal and early postnatal programming of hypertension. [19794108] Am J Physiol Renal Physiol 298(2): F235-47 (2010)
2008 257	Programming of hypertension: the nervous kidney. [18463313] Am J Physiol Renal Physiol 295(1): F27-8 (2008)
2010 258	The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. [20798254] Clin J Am Soc Nephrol 5(10): 1893-903 (2010)
2007 259	Resistant hypertension: a methodological approach to diagnosis and treatment. [17679742] Saudi J Kidney Dis Transpl 18(3): 337-45 (2007)
2011 260	Altered neural and vascular mechanisms in hypertension. [21615201] Physiol Res 60(3): 381-402 (2011)
2010 261	The role of renin-angiotensin system in prothrombotic state in essential hypertension. [19249905] Physiol Res 59(1): 13-23 (2010)
2009 262	Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension. [19503776] Clin Interv Aging 4(-): 137-51 (2009)
2008 263	NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. [18227481] Diabetes Care 31 Suppl 2(-): S170-80 (2008)
2010 264	On redefining hypertension. [20844617] Tex Heart Inst J 37(4): 439-41 (2010)
2011 265	Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly. [21878862] Pol Arch Med Wewn 121(7-8): 253-8 (2011)
2010 266	Genetic architecture of complex traits predisposing to nephropathy: hypertension. [20347644] Semin Nephrol 30(2): 150-63 (2010)
2011 267	Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. [21339086] Curr Opin Pharmacol 11(2): 180-6 (2011)
2010 268	Role of the adaptive immune system in hypertension. [20167535] Curr Opin Pharmacol 10(2): 203-7 (2010)
2010 269	Aldosterone renin ratio in patients with resistant hypertension. [20360029] QJM 103(11): 897-9 (2010)
2008 270	New techniques for assessing arterial stiffness. [18358423] Diabetes Metab 34 Suppl 1(-): S21-6 (2008)
2010 271	Hypertension and renal calcium transport. [21170867] J Nephrol 23 Suppl 16(): S112-7 (2010)
2009 272	Fifty years of thiazide diuretic therapy for hypertension. [19901136] Arch Intern Med 169(20): 1851-6 (2009)
2010 273	Excess dietary salt intake alters the excitability of central sympathetic networks. [20434471] Physiol Behav 100(5): 519-24 (2010)
2011 274	Current status of aggressive blood pressure control. [21499494] World J Cardiol 3(3): 65-71 (2011)
2011 275	Inflammation in the pathophysiology of essential hypertension. [20437401] J Nephrol 24(1): 23-34 (2011)
2009 276	Oral drugs for hypertensive urgencies: systematic review and meta-analysis. [20512292] Sao Paulo Med J 127(6): 366-72 (2009)
2007 277	Non-pharmacological management of hypertension. [18025751] Indian J Med Sci 61(11): 616-24 (2007)
2007 278	Scleroderma renal crisis. [17259685] Indian J Med Sci 61(2): 71-2 (2007)
2007 279	Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. [17887997] Int J Clin Pract 61(12): 2093-102 (2007)
2008 280	Organic anion transporter 3 inhibitors as potential novel antihypertensives. [18973812] Pharmacol Res 58(5-6): 257-61 (2008)
2010 281	Physiologic tailoring of treatment in resistant hypertension. [21532778] Curr Cardiol Rev 6(2): 119-23 (2010)
2007 282	Modern antihypertensive therapy: a report from the 22nd annual meeting of the American Society of Hypertension. [18297145] Timely Top Med Cardiovasc Dis 11(-): E17 (2007)
2007 283	New joint European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. [18297146] Timely Top Med Cardiovasc Dis 11(-): E18 (2007)
2007 284	New research and new guidelines for the treatment of hypertension: a report from the 17th European Meeting on Hypertension. [18297147] Timely Top Med Cardiovasc Dis 11(-): E19 (2007)
2005 285	Antihypertensive drug interactions. [15824761] Timely Top Med Cardiovasc Dis 9(-): E2 (2005)
2011 286	Vascular stiffness and increased pulse pressure in the aging cardiovascular system. [21845218] Cardiol Res Pract 2011(-): 263585 (2011)
2011 287	Update on diagnosis and treatment of resistant hypertension. [21725176] Iran J Kidney Dis 5(4): 215-27 (2011)
2008 288	Childhood hypertension: new concepts, definitions, and diagnostic evaluations. [19377224] Iran J Kidney Dis 2(3): 123-6 (2008)
2011 289	High-salt diet and hypertension: focus on the renin-angiotensin system. [21071956] Kidney Blood Press Res 34(1): 1-11 (2011)
2011 290	The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension. [21207253] Curr Hypertens Rep 13(2): 109-15 (2011)
2010 291	Masked hypertension: evidence of the need to treat. [20694858] Curr Hypertens Rep 12(5): 349-55 (2010)
2009 292	The role of the sympathetic nervous system in obesity-related hypertension. [19442330] Curr Hypertens Rep 11(3): 206-11 (2009)
2010 293	Novel drugs targeting hypertension revisited. [20844362] J Cardiovasc Pharmacol 56(3): 213-4 (2010)
2010 294	Targeting epoxides for organ damage in hypertension. [20531214] J Cardiovasc Pharmacol 56(4): 329-35 (2010)
2010 295	20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. [20930591] J Cardiovasc Pharmacol 56(4): 336-44 (2010)
2002 296	The sympathetic nervous system: the muse of primary hypertension. [11986898] J Hum Hypertens 16 Suppl 1(-): S64-9 (2002)
2002 297	Diuretics in the therapy of hypertension. [11986901] J Hum Hypertens 16 Suppl 1(-): S78-83 (2002)
2002 298	Angiotensin II receptor antagonists role in arterial hypertension. [11986904] J Hum Hypertens 16 Suppl 1(-): S93-9 (2002)
2002 299	Diuretics in the treatment of patients who present congestive heart failure and hypertension. [11986906] J Hum Hypertens 16 Suppl 1(-): S104-13 (2002)
2002 300	Update on the use of calcium antagonists on hypertension. [11986907] J Hum Hypertens 16 Suppl 1(-): S114-7 (2002)
2002 301	Sympatholytic therapy in primary hypertension: a user friendly role for the future. [11986908] J Hum Hypertens 16 Suppl 1(-): S118-23 (2002)
2002 302	Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. [11896503] J Hum Hypertens 16(3): 153-8 (2002)
2002 303	Isolated systolic hypertension: a new challenge in medicine. [11986893] J Hum Hypertens 16 Suppl 1(-): S44-7 (2002)
2002 304	Doxazosin, an inferior antihypertensive agent? [12037690] J Hum Hypertens 16(6): 375-7 (2002)
2010 305	The epidemiology and management of severe hypertension. [19440209] J Hum Hypertens 24(1): 9-18 (2010)
2010 306	Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. [20226958] Prog Cardiovasc Dis 52(5): 401-9 (2010)
2008 307	Electrocardiographic left ventricular hypertrophy with strain pattern: prevalence, mechanisms and prognostic implications. [18320088] Cardiovasc J Afr 19(1): 39-45 (2008)
2009 308	Characterization and treatment of resistant hypertension. [19863864] Curr Cardiol Rep 11(6): 407-13 (2009)
2010 309	Antihypertensive agents in hemodialysis patients: a current perspective. [20374548] Semin Dial 23(3): 290-7 (2010)
2008 310	Are statins effective for simultaneously treating dyslipidemias and hypertension? [17662294] Atherosclerosis 196(1): 1-8 (2008)
2009 311	Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review. [19327149] Cardiovasc Diabetol 8(-): 18 (2009)
2010 312	Optimal management of hypertension in elderly patients. [21949630] Integr Blood Press Control 3(-): 145-53 (2010)
2011 313	Hypertension in chronic kidney disease: navigating the evidence. [21747971] Int J Hypertens 2011(-): 132405 (2011)
2011 314	Prevalence, risk factors, and management of prehypertension. [22121474] Int J Hypertens 2011(-): 605359 (2011)
2010 315	PPARs in the Renal Regulation of Systemic Blood Pressure. [20613959] PPAR Res 2010(-): 698730 (2010)
2010 316	Arterial baroreceptors in the management of systemic hypertension. [20037502] Med Sci Monit 16(1): RA1-8 (2010)
2008 317	Heat stress and baroreflex regulation of blood pressure. [18981943] Med Sci Sports Exerc 40(12): 2063-70 (2008)
2009 318	Collecting Duct Renin: A major player in Angiotensin II-dependent Hypertension. [20046983] J Am Soc Hypertens 3(2): 96-104 (2009)
2011 319	Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension. [21755262] Braz J Med Biol Res 44(9): 871-6 (2011)
2010 320	Control of elevated blood pressure in acute intracerebral hemorrhage. [21173835] F1000 Med Rep 2(-): 75 (2010)
2010 321	Recent advances in the management of hypertension. [20948867] F1000 Med Rep 2(-): - (2010)
2009 322	Cellular mediators of renal vascular dysfunction in hypertension. [19225145] Am J Physiol Regul Integr Comp Physiol 296(4): R1001-18 (2009)
2009 323	The pathophysiology of hypertension in systemic lupus erythematosus. [19158408] Am J Physiol Regul Integr Comp Physiol 296(4): R1258-67 (2009)
2010 324	Diagnosis of secondary hypertension: an age-based approach. [21166367] Am Fam Physician 82(12): 1471-8 (2010)
2010 325	Dopamine and G protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation. [20153824] Biochim Biophys Acta 1802(12): 1259-67 (2010)
2010 326	Regulation of GPCR signaling in hypertension. [20060896] Biochim Biophys Acta 1802(12): 1268-75 (2010)
2010 327	T cells and blood vessels: costimulation turns up the pressure. [21126974] Circulation 122(24): 2495-8 (2010)
2011 328	Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT. [21167012] Cardiovasc Ther 29(1): 68-76 (2011)
2010 329	Prehypertension: the rationale for early drug therapy. [20553286] Cardiovasc Ther 28(6): 339-43 (2010)
2010 330	Overnight rostral fluid shift and obstructive sleep apnea in treatment resistant hypertension: connecting the dots clarifies the picture. [21059995] Hypertension 56(6): 1040-1 (2010)
PMC 331	Effect of sphingosine kinase 1 inhibition on blood pressure. [23109673] FASEB J 27(2):656-64 (2013)
PMC 332	Aldosterone synthase inhibitors in hypertension: current status and future possibilities. [24570839] JRSM Cardiovasc Dis 3():2048004014522440 (2014)
PMC 333	Cost-effectiveness of secondary screening modalities for hypertension. [23263535] Blood Press Monit 18(1):1-7 (2013)
PMC 334	American Heart Association Scientific Sessions 2013: Agents for Hypertension, Heart Failure, and Acute Myocardial Infarction. [24672217] P T 39(1):65-7 (2014)
PMC 335	Diabetes: treating hypertension. [22456232] Clin Evid (Online) 2012(): (2012)
PMC 336	Increasing complexity: which drug class to choose for treatment of hypertension in the elderly? [24711696] Clin Interv Aging 9():459-75 (2014)
PMC 337	Hypoxia stress test reveals exaggerated cardiovascular effects in hypertensive rats after exposure to the air pollutant acrolein. [23335627] Toxicol Sci 132(2):467-77 (2013)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Arterial hypertension (BASKET).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Arterial hypertension (BASKET).php on line 92